CORDIS
EU research results

CORDIS

English EN

Targeting chromatin in cancer: histone deacetylases and differentiation therapy of acute myeloid leukemias (CHROMATIN AND CANCER)

Project information

Grant agreement ID: QLG1-CT-2001-01935

  • Start date

    1 November 2001

  • End date

    31 October 2004

Funded under:

FP5-LIFE QUALITY

  • Overall budget:

    € 2 649 345

  • EU contribution

    € 1 959 106

Coordinated by:

ISTITUTO EUROPEO DI ONCOLOGIA SRL

Italy

Objective

Acetylation/deacetylation by histone acetylases (HAT) and deacetylases (HDAC) regulates gene transcription and specific functions, such as tumour suppression by p53. Abnormalities of HAT or HDAC are frequently found in tumours. Targeting of HDAC by small compounds is effective in the differentiation treatment of a small subset of leukaemia. We aim to determine whether HDACs are suitable general targets for cancer drug discovery. We will characterize the mechanisms of activities of HDAC/HAT in normal and cancer cells, and screen tumours with a panel of HDAC inhibitors. Our experimental approaches range from biochemistry, to molecular biology, to post-genomics (proteomics and nanotechnology), and include the functional validation of compounds and demonstrated mechanisms in animal model systems and tumour samples. Final objective is the design of differentiation treatment protocols for leukaemia and myelodysplastic syndromes.

Leaflet | Map data © OpenStreetMap contributors, Credit: EC-GISCO, © EuroGeographics for the administrative boundaries

Coordinator

ISTITUTO EUROPEO DI ONCOLOGIA SRL

Address

Via Ripamonti 435
20141 Milano

Italy

Participants (9)

CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE

France

GEORG-SPEYER-HAUS - CHEMOTHERAPEUTISCHES FORSCHUNGSINSTITUT

Germany

HOSPITAL UNIVERSITARIO DE LA FE SEVASA

Spain

INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE

France

INSTITUT PASTEUR

France

SECONDA UNIVERSITA DEGLI STUDI DI NAPOLI

Italy

STICHTING KATHOLIEKE UNIVERSITEIT

Netherlands

UNIVERSITY OF ROME "LA SAPIENZA"

Italy

University of Cambridge

United Kingdom

Project information

Grant agreement ID: QLG1-CT-2001-01935

  • Start date

    1 November 2001

  • End date

    31 October 2004

Funded under:

FP5-LIFE QUALITY

  • Overall budget:

    € 2 649 345

  • EU contribution

    € 1 959 106

Coordinated by:

ISTITUTO EUROPEO DI ONCOLOGIA SRL

Italy